...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of biomedical materials research. Part B, Applied biomaterials. >Use of recombinant human osteogenic protein-1 for the repair of subchondral defects in articular cartilage in goats.
【24h】

Use of recombinant human osteogenic protein-1 for the repair of subchondral defects in articular cartilage in goats.

机译：重组人成骨蛋白1在修复山羊关节软骨软骨下缺损中的应用。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The objective of this pilot study was to examine in vivo the potential of recombinant human osteogenic protein-1 (rhOP-1, also called bone morphogenetic protein-7, BMP-7) for treatment of subchondral lesions by induction of new hyaline cartilage formation. Subchondral left knee defects in 17 mature goats were treated with fresh coagulated blood mixed with (1) rhOP-1 combined with collagen (OP-1 device, 400 microgram/mL); (2) rhOP-1 alone (OP-1 peptide, 200 microgram/mL); (3) OP-1 device with small particles of autologous ear perichondrium; (4) OP-1 peptide with small particles of autologous ear perichondrium; or (5) autologous ear perichondrium alone (controls). rhOP-1 was combined with either collagen (OP-1 device) or not (OP-1 peptide). The defects were closed with a periosteal flap. The formation of cartilage tissue was studied by histologic and biochemical evaluation at 1, 2, and 4 months after implantation. One and 2 months after implantation there were no obvious differences between control and rhOP-1-treated defects. Four months after implantation, only one out of three controls (without rhOP-1) showed beginning signs of cartilage formation while all four rhOP-1-treated defects were completely or partly filled with cartilage. A significant linear relationship was found between rhOP-1 concentration and the total amount of aggrecan in the defects. These results suggest that implantation of rhOP-1 promotes cartilage formation in subchondral defects in goats at 4 months after implantation. Therefore, rhOP-1 could be a novel factor for regeneration of cartilage in articular cartilage defects. Copyright 2000 John Wiley & Sons, Inc.
机译：这项初步研究的目的是体内研究重组人成骨蛋白-1（rhOP-1，也称为骨形态发生蛋白-7，BMP-7）通过诱导新的透明软骨形成来治疗软骨下病变的潜力。用新鲜凝结的血液与（1）rhOP-1和胶原蛋白（OP-1装置，400微克/毫升）混合，处理17头成熟山羊的软骨下左膝缺损。 （2）单独的rhOP-1（OP-1肽，200微克/毫升）; （3）自体耳软骨膜细小颗粒的OP-1装置; （4）具有自体耳软骨膜小颗粒的OP-1肽;或（5）单独使用自体耳软骨膜（对照）。 rhOP-1与胶原蛋白（OP-1设备）或不与胶原蛋白（OP-1肽）组合。用骨膜瓣封闭缺损。在植入后1、2和4个月，通过组织学和生化评估研究软骨组织的形成。植入后1个月和2个月，对照和rhOP-1处理的缺损之间无明显差异。植入后四个月，三个对照（无rhOP-1）中只有一个显示出开始形成软骨的迹象，而所有四个rhOP-1处理的缺损完全或部分充满了软骨。发现缺陷中rhOP-1浓度与聚集蛋白聚糖总量之间存在显着的线性关系。这些结果表明，rhOP-1的植入促进了山羊植入后4个月软骨下缺损的软骨形成。因此，rhOP-1可能是关节软骨缺损中软骨再生的新因素。版权所有2000 John Wiley＆Sons，Inc.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号